Amneal Pharmaceuticals (AMRX) Gross Margin (2017 - 2026)

Amneal Pharmaceuticals' Gross Margin history runs 10 years deep, the most recent figure standing at 44.31% for Q1 2026.

• In Q1 2026, Gross Margin rose 751.0% year-over-year to 44.31%; the TTM figure through Mar 2026 stood at 38.66% (up 197.0% YoY), while the FY2025 annual figure was 36.88%, up 36.0% from the prior year.
• Gross Margin was 44.31% for Q1 2026 at Amneal Pharmaceuticals, up from 36.5% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 6019.69% in Q1 2022 to a low of 13.61% in Q4 2022.
• Historically, Gross Margin has averaged 385.45% across 5 years, with a median of 36.11% in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Margin soared 598084 bps in 2022, then plunged 598773 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 13.61% in 2022, then jumped by 326 bps to 30.77% in 2023, then grew by 17 bps to 35.98% in 2024, then rose by 1 bps to 36.5% in 2025, then gained by 21 bps to 44.31% in 2026.
• The last three Gross Margin figures came in at 44.31% (Q1 2026), 36.5% (Q4 2025), and 34.92% (Q3 2025), per Business Quant data.